Partner Adam Schoen serves as co-leader of the Global IP practice group and Global Life sciences group for Brown Rudnick LLP . With multidisciplinary practice across patent practice, Schoen primarily engages with pharmaceutical, life sciences, and biotech companies, including recent deals with figures up to $4 billion.
Legal 500 Editorial commentary
Phone
+1.617.856.8132
Email
Profile

Accolades

Boston Elite

Profile

Work Department
Intellectual Property and Life Sciences
Position

Partner

Career

Adam Schoen is a partner and co-practice group leader of Brown Rudnick's Global Intellectual Property Practice Group and Global Life Sciences Group. Adam has been in the life sciences industry for over 20 years and has over 15 years of experience advising life sciences and medical device funds, companies, and academic institutions. Adam helps his clients build, grow, invest in, buy, and sell companies of all sizes all over the world. Adam’s practice is multidisciplinary, encompassing all aspects of patent preparation and prosecution, portfolio development, product clearance, freedom to operate analysis, intellectual property due diligence, licensing, and other agreement work.

Adam has experience developing and implementing worldwide patent strategies across the life sciences industry. He works with a variety of technologies, such as small molecule therapeutics, biologics (including gene therapies and immunotherapeutics), gene editing technology, next generation sequencing technologies, microfluidics and droplet based technologies, diagnostics (including cancer and fertility diagnostics), medical device technology (ophthalmology, cardiology, orthopedics, otolaryngology, neurology, and spine), medical imaging technology (ultrasound and OCT), mass spectrometry, and digital health products.

Prior to law school, Adam was a scientist of analytical chemistry for ArQule, a combinatorial chemistry and drug discovery company, and a scientist at Millennium Pharmaceuticals.

Content supplied by Brown Rudnick LLP

Key clients

  • Kate Therapeutics Vor Bio Voxelron Latigo Bio Navigator Medicines AllRock Bio

Work highlights

Advised preclinical-stage biotech startup Kate Therapeutics on all IP-related aspects from its founding in 2020, to its sale in 2024, valued at $1.1 billion.
Advised public company Vor Bio in its exclusive license agreement with a leading Chinese biopharmaceutical company, which granted them international development and commercialisation rights of their novel dual-target fusion protein.
Advised Latigo Biotherapeutics on IP matters related to its $150 million Series B financing for development of nonopioid pain medication, following counsel on previous $135 million Series A financing.